Risk of Diabetes in Patients with Long-Standing Graves' Disease: A Longitudinal Study
- PMID: 34915605
- PMCID: PMC8743588
- DOI: 10.3803/EnM.2021.1251
Risk of Diabetes in Patients with Long-Standing Graves' Disease: A Longitudinal Study
Abstract
Background: The detrimental effects of excessive thyroid hormone on glucose metabolism have been widely investigated. However, the risk of diabetes in patients with long-standing hyperthyroidism, especially according to treatment modality, remains uncertain, with few longitudinal studies.
Methods: The risk of diabetes in patients with Graves' disease treated with antithyroid drugs (ATDs) for longer than the conventional duration (≥2 years) was compared with that in age-and sex-matched controls. The risk was further compared according to subsequent treatment modalities after a 24-month course of ATD: continuation of ATD (ATD group) vs. radioactive iodine ablation (RIA) group.
Results: A total of 4,593 patients were included. Diabetes was diagnosed in 751 (16.3%) patients over a follow-up of 7.3 years. The hazard ratio (HR) for diabetes, after adjusting for various known risk factors, was 1.18 (95% confidence interval [CI], 1.10 to 1.28) in patients with hyperthyroidism. Among the treatment modality groups, the RIA group (n=102) had a higher risk of diabetes than the ATD group (n=4,491) with HR of 1.56 (95% CI, 1.01 to 2.42). Further, the risk of diabetes increased with an increase in the ATD treatment duration (P for trend=0.019).
Conclusion: The risk of diabetes was significantly higher in patients with long-standing Graves' disease than in the general population, especially in patients who underwent RIA and prolonged ATD treatment. Special attention to hyperglycemia during follow-up along with effective control of hyperthyroidism may be necessary to reduce the risk of diabetes in these patients.
Keywords: Antithyroid agents; Diabetes mellitus; Graves disease; Hyperthyroidism; Radioiodine ablation.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures
Comment in
-
Diabetes and Hyperthyroidism: Is There a Causal Link?Endocrinol Metab (Seoul). 2021 Dec;36(6):1175-1177. doi: 10.3803/EnM.2021.602. Epub 2021 Dec 28. Endocrinol Metab (Seoul). 2021. PMID: 34986300 Free PMC article. No abstract available.
References
-
- Cooper DS. Hyperthyroidism. Lancet. 2003;362:459–68. - PubMed
-
- Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97:4549–58. - PubMed
-
- Brito JP, Schilz S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, et al. Antithyroid drugs-the most common treatment for Graves’ disease in the United States: a nationwide population-based study. Thyroid. 2016;26:1144–5. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
